Sign In
Buy ACON
$2.89
-0.150 (-4.93%)
At Close: Jun 23, 2026
Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub
07:00am, Wednesday, 10'th Jun 2026
BROOMFIELD, Colo., June 10, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarke
Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform
07:00am, Tuesday, 09'th Jun 2026
Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driven platform for chronic low back pain.
Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform
07:00am, Tuesday, 09'th Jun 2026
Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driven platform for chronic low back pain. Program aims to follow successful reimbursement wins in the UK th
Aclarion Rejects Echo Lake Capital's Unsolicited Acquisition Proposal
07:06am, Monday, 08'th Jun 2026
PR Audio: BROOMFIELD, Colo., June 8, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
Aclarion Rejects Echo Lake Capital's Unsolicited Acquisition Proposal
07:05am, Monday, 08'th Jun 2026
BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging b
Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting
07:02am, Monday, 08'th Jun 2026
BROOMFIELD, Colo., June 8, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial
Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting
07:00am, Monday, 08'th Jun 2026
BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging bi
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
06:00am, Wednesday, 03'rd Jun 2026
Broomfield, CO, June 3, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-st
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
06:00am, Wednesday, 03'rd Jun 2026
Expands availability of Nociscan in the greater Los Angeles area with leading neuroscience group Adds to growing body of real-world evidence with study comparing chemical biomarker data from Nociscan
Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study
06:04am, Monday, 01'st Jun 2026
Award-winning, NIH funded study indicates that immune-associated biological signatures may play a role in some cases of back pain.
Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study
06:00am, Monday, 01'st Jun 2026
Award-winning, NIH funded study indicates that immune-associated biological signatures may play a role in some cases of back pain Nociscan's underlying MRS technology enabled measurement of intradisca
Aclarion, Inc. Comments on Echo Lake Capital's Letter and Unsolicited Proposal
03:04pm, Thursday, 28'th May 2026
BROOMFIELD, Colo., May 28, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare
Aclarion, Inc. Comments on Echo Lake Capital's Letter and Unsolicited Proposal
02:49pm, Thursday, 28'th May 2026
BROOMFIELD, Colo., May 28, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and propr
Echo Lake Capital Offers To Acquire Aclarion Inc.
08:00am, Thursday, 28'th May 2026
Offers $4.00 per share in cash plus CVR Stock currently trades below the value of its cash and other assets Believes company's public shell worth at least another $6 million if Board effected a revers
Aclarion (ACON) Upgraded to Buy: Here's Why
01:01pm, Tuesday, 19'th May 2026
Aclarion (ACON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
